An observational prospective single-center study to evaluate the short and medium term effect of Sacubitril/Valsartan treatment on Myocardial work parameters and the prognostic value of myocardial work in heart failure patients
Latest Information Update: 30 Oct 2020
Price :
$35 *
At a glance
- Drugs Sacubitril/valsartan (Primary)
- Indications Coronary artery disease; Heart failure; Myocardial disorders
- Focus Adverse reactions; Therapeutic Use
- 01 Sep 2020 Results presented at the ESC Congress 2020 - Annual Congress of the European Society of Cardiology
- 22 Apr 2020 New trial record
- 02 Apr 2020 Results published in the American Journal of Cardiology